Pentraxin-3 is upregulated in the central nervous system during MS and EAE, but does not modulate experimental neurological disease

European Journal of Immunology

Volumn 46, Issue 3, 2016, Pages 701-711

  Ummenthum, Kimberley ^a   Peferoen, Laura A N ^a   Finardi, Annamaria ^b   Baker, David ^c   Pryce, Gareth ^c   Mantovani, Alberto ^d   Bsibsi, Malika ^e   Bottazzi, Barbara ^d   Peferoen Baert, Regina ^a   van der Valk, Paul ^a   Garlanda, Cecilia ^d   Kipp, Markus ^f   Furlan, Roberto ^b   van Noort, Johannes M ^e   Amor, Sandra ^a,c  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^e Delta Crystallon BV   (Netherlands)

^f UNIVERSITY OF MUNICH   (Germany)

Author keywords

Experimental autoimmune encephalomyelitis (EAE); Innate immunity; Microglia; Multiple Sclerosis (MS); Pentraxin 3 (PTX3)

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; MYELIN; PENTRAXIN 3; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN HSPB5; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; C REACTIVE PROTEIN; SERUM AMYLOID P; TOLL LIKE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOZZI MOUSE; CENTRAL NERVOUS SYSTEM; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL DEMYELINATION; EXPERIMENTAL NEUROLOGIC DISEASE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOLOGICAL TOLERANCE; MALE; MICROGLIA; MOUSE; MULTIPLE SCLEROSIS; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; SPINAL CORD; T LYMPHOCYTE; UPREGULATION; WHITE MATTER LESION; WILD TYPE MOUSE; ANIMAL; BRAIN; CEREBROSPINAL FLUID; DISEASE MODEL; GENETICS; IMMUNOLOGY; INFLAMMATION; MACROPHAGE; METABOLISM; MYELIN SHEATH; PATHOLOGY; SPINE;

ANIMALS; BRAIN; C-REACTIVE PROTEIN; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; INFLAMMATION; MACROPHAGES; MICE; MICE, BIOZZI; MICROGLIA; MULTIPLE SCLEROSIS; MYELIN SHEATH; PHAGOCYTOSIS; SERUM AMYLOID P-COMPONENT; SPINE; TOLL-LIKE RECEPTORS; UP-REGULATION;

EID: 84959343429     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201545950     Document Type: Article

References (45)

1. Bottazzi, B., Doni, A., Garlanda, C. and Mantovani, A., An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010. 28: 157-183.
2. Garlanda, C., Maina, V., Cotena, A. and Moalli, F., The soluble pattern recognition receptor pentraxin-3 in innate immunity, inflammation and fertility. J. Reprod. Immunol. 2009. 83: 128-133.
3. Alles, V. V., Bottazzi, B., Peri, G., Golay, J., Introna, M. and Mantovani, A., Inducible expression of PTX3, a new member of the pentraxin family, in human mononuclear phagocytes. Blood 1994. 84: 3483-3493.
4. Kravitz, M. S., Pitashny, M. and Shoenfeld, Y., Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J. Clin. Immunol. 2005. 25: 582-591.
5. Cunningham, C., Wilcockson, D. C., Campion, S., Lunnon, K. and Perry, V. H., Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J. Neurosci. 2005. 25: 9275-9284.
6. Jeon, J.-W., Jung, J.-G., Shin, E.-C., Choi, H. I., Kim, H. Y., Cho, M.-L., Kim, S.-W. et al., Soluble CD93 induces differentiation of monocytes and enhances TLR responses. J. Immunol. 2010. 185: 4921-4927.
7. Deban, L., Jaillon, S., Garlanda, C., Bottazzi, B. and Mantovani, A., Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res. 2011. 343: 237-249.
8. Reading, P. C., Bozza, S., Gilbertson, B., Tate, M., Moretti, S., Job, E. R., Crouch, E. C. et al., Antiviral activity of the long chain pentraxin PTX3 against influenza viruses. J. Immunol. 2008. 180: 3391-3398.
9. Moalli, F., Paroni, M., Véliz Rodriguez, T., Riva, F., Polentarutti, N., Bottazzi, B., Valentino, S. et al., The therapeutic potential of the humoral pattern recognition molecule PTX3 in chronic lung infection caused by Pseudomonas aeruginosa. J. Immunol. 2011. 186: 5425-5434.
10. Nauta, A. J., Bottazzi, B., Mantovani, A., Salvatori, G., Kishore, U., Schwaeble, W. J., Gingras, A. R. et al., Biochemical and functional characterization of the interaction between pentraxin 3 and C1q. Eur. J. Immunol. 2003. 33: 465-473.
11. Agrawal, A., Singh, P. P., Bottazzi, B., Garlanda, C. and Mantovani, A., Pattern recognition by pentraxins. Adv. Exp. Med. Biol. 2009. 653: 98-116.
12. Rodriguez-Grande, B., Varghese, L., Molina-Holgado, F., Rajkovic, O., Garlanda, C., Denes, A. and Pinteaux, E., Pentraxin 3 mediates neurogenesis and angiogenesis after cerebral ischaemia. J. Neuroinflammation. 2015. 12: 15.
13. Ravizza, T., Moneta, D., Bottazzi, B., Peri, G., Garlanda, C., Hirsch, E., Richards, G. J. et al., Dynamic induction of the long pentraxin PTX3 in the CNS after limbic seizures: evidence for a protective role in seizure-induced neurodegeneration. Neuroscience 2001. 105: 43-53.
14. Lech, M., Römmele, C., Gröbmayr, R., Eka Susanti, H., Kulkarni, O. P., Wang, S., Gröne, H.-J. et al., Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury. Kidney Int. 2013. 83: 647-661.
15. Jeon, H., Lee, S., Lee, W.-H. and Suk, K., Analysis of glial secretome: the long pentraxin PTX3 modulates phagocytic activity of microglia. J. Neuroimmunol. 2010. 229: 63-72.
16. Lampron, A., Larochelle, A., Laflamme, N., Préfontaine, P., Plante, M.-M., Sánchez, M. G., Yong, V. W. et al., Inefficient clearance of myelin debris by microglia impairs remyelinating processes. J. Exp. Med. 2015. 212: 481-495.
17. Ko, C.-Y., Chang, L.-H., Lee, Y.-C., Sterneck, E., Cheng, C.-P., Chen, S.-H., Huang, A.-M. et al., CCAAT/enhancer binding protein delta (CEBPD) elevating PTX3 expression inhibits macrophage-mediated phagocytosis of dying neuron cells. Neurobiol. Aging. 2012. 33: 422.e11-25.
18. Palin, K., Cunningham, C., Forse, P., Perry, V. H. and Platt, N., Systemic inflammation switches the inflammatory cytokine profile in CNS Wallerian degeneration. Neurobiol. Dis. 2008. 30: 19-29.
19. Foo, S.-S., Chen, W., Taylor, A., Sheng, K.-C., Yu, X., Teng, T.-S., Reading, P. C. et al., Role of pentraxin 3 in shaping arthritogenic alphaviral disease: from enhanced viral replication to immunomodulation. PLoS Pathog. 2015. 11:e1004649.
20. Agnello, D., Carvelli, L., Muzio, V., Villa, P., Bottazzi, B., Polentarutti, N., Mennini, T. et al., Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J. Neuroimmunol. 2000. 109: 105-111.
21. Wang, H., Wang, K., Wang, C., Zhong, X., Qiu, W. and Hu, X., Increased plasma levels of pentraxin 3 in patients with multiple sclerosis and neuromyelitis optica. Mult. Scler. 2013. 19: 926-931.
22. Kipp, M., van der Star, B., Vogel, D. Y. S., Puentes, F., van der Valk, P., Baker, D. and Amor, S., Experimental in vivo and in vitro models of multiple sclerosis: EAE and beyond. Mult Scler Relat Disord. 2012. 1: 15-28.
23. Van der Valk, P. and Amor, S., Preactive lesions in multiple sclerosis. Curr. Opin. Neurol. 2009. 22: 207-213.
24. Banati, R. B., Newcombe, J., Gunn, R. N., Cagnin, A., Turkheimer, F., Heppner, F., Price, G. et al., The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000. 123 (Pt 11): 2321-2337.
25. Miller, D. H., Thompson, A. J. and Filippi, M., Magnetic resonance studies of abnormalities in the normal appearing white matter and grey matter in multiple sclerosis. J. Neurol. 2003. 250: 1407-1419.
26. Van Horssen, J., Singh, S., van der Pol, S., Kipp, M., Lim, J. L., Peferoen, L., Gerritsen, W. et al., Clusters of activated microglia in normal-appearing white matter show signs of innate immune activation. J Neuroinflammation. 2012. 9: 156.
27. Bsibsi, M., Peferoen, L. A. N., Holtman, I. R., Nacken, P. J., Gerritsen, W. H., Witte, M. E., van Horssen, J. et al., Demyelination during multiple sclerosis is associated with combined activation of microglia/macrophages by IFN-γ and alpha B-crystallin. Acta Neuropathol. 2014. 128: 215-229.
28. Peferoen, L. A. N., Vogel, D. Y. S., Ummenthum, K., Breur, M., Heijnen, P. D. A. M., Gerritsen, W. H., Peferoen-Baert, R. M. B. et al., Activation status of human microglia is dependent on lesion formation stage and remyelination in multiple sclerosis. J. Neuropathol. Exp. Neurol. 2015. 74: 48-63.
29. Van Noort, J. M., Bsibsi, M., Gerritsen, W. H., van der Valk, P., Bajramovic, J. J., Steinman, L. and Amor, S., Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 2010. 69: 694-703.
30. Bsibsi, M., Holtman, I. R., Gerritsen, W. H., Eggen, B. J. L., Boddeke, E., van der Valk, P., van Noort, J. M. et al., Alpha-B-crystallin induces an immune-regulatory and antiviral microglial response in preactive multiple sclerosis lesions. J. Neuropathol. Exp. Neurol. 2013. 72: 970-979.
31. Van Noort, J. M., Bsibsi, M., Nacken, P. J., Gerritsen, W. H., Amor, S., Holtman, I. R., Boddeke, E. et al., Activation of an immune-regulatory macrophage response and inhibition of lung inflammation in a mouse model of COPD using heat-shock protein alpha B-crystallin-loaded PLGA microparticles. Biomaterials 2013. 34: 831-840.
32. Vogel, D. Y. S., Vereyken, E. J. F., Glim, J. E., Heijnen, P. D. A. M., Moeton, M., van der Valk, P., Amor, S. et al., Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. J Neuroinflammation. 2013. 10: 35.
33. Esen, N. and Kielian, T., Central role for MyD88 in the responses of microglia to pathogen-associated molecular patterns. J. Immunol. 2006. 176: 6802-6811.
34. Masilamoni, J. G., Jesudason, E. P., Baben, B., Jebaraj, C. E., Dhandayuthapani, S. and Jayakumar, R., Molecular chaperone alpha-crystallin prevents detrimental effects of neuroinflammation. Biochim. Biophys. Acta 2006. 1762: 284-293.
35. Ousman, S. S., Tomooka, B. H., van Noort, J. M., Wawrousek, E. F., O'Connor, K. C., Hafler, D. A., Sobel, R. A. et al., Protective and therapeutic role for alphaB-crystallin in autoimmune demyelination. Nature 2007. 448: 474-479.
36. Pangratz-Fuehrer, S., Kaur, K., Ousman, S. S., Steinman, L. and Liao, Y. J., Functional rescue of experimental ischemic optic neuropathy with αB-crystallin. Eye (Lond). 2011. 25: 809-817.
37. Klopstein, A., Santos-Nogueira, E., Francos-Quijorna, I., Redensek, A., David, S., Navarro, X. and López-Vales, R., Beneficial effects of αB-crystallin in spinal cord contusion injury. J. Neurosci. 2012. 32: 14478-14488.
38. Holley, J. E., Newcombe, J., Whatmore, J. L. and Gutowski, N. J., Increased blood vessel density and endothelial cell proliferation in multiple sclerosis cerebral white matter. Neurosci. Lett. 2010. 470: 65-70.
39. Zhang, L., Liu, S.-H., Wright, T. T., Shen, Z.-Y., Li, H.-Y., Zhu, W., Potempa, L. A. et al., C-reactive protein directly suppresses Th1 cell differentiation and alleviates experimental autoimmune encephalomyelitis. J. Immunol. 2015. 194: 5243-5252.
40. Ji, Z., Ke, Z.-J. and Geng, J.-G., SAP suppresses the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. Immunol. Cell Biol. 2012. 90: 388-395.
41. Al-Izki, S., Pryce, G., O'Neill, J. K., Butter, C., Giovannoni, G., Amor, S. and Baker, D., Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Mult Scler Relat Disord. 2012. 1: 29-38.
42. Kilkenny, C., Browne, W., Cuthill, I. C., Emerson, M. and Altman, D. G., NC3Rs Reporting Guidelines Working Group. Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br. J. Pharmacol. 2010. 160: 1577-1579.
43. Brini, E., Ruffini, F., Bergami, A., Brambilla, E., Dati, G., Greco, B., Cirillo, R. et al., Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss. J. Neuroimmunol. 2009. 209: 33-39.
44. Pryce, G., O'Neill, J. K., Croxford, J. L., Amor, S., Hankey, D. J., East, E., Giovannoni, G. et al., Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J. Neuroimmunol. 2005. 165: 41-52.
45. Ruijter, J. M., Ramakers, C., Hoogaars, W. M. H., Karlen, Y., Bakker, O., van den Hoff, M. J. B. and Moorman, A. F. M., Amplification efficiency: linking baseline and bias in the analysis of quantitative PCR data. Nucleic Acids Res. 2009. 37:e45.